Client's Challenge: Oncologists were not sold on the new indication of an older product and had combination concerns. Oncologists familiar with using this drug for many tumor sites and types were unacquainted with its efficacy and safety data in the new indication. Treaters also had reservations about combination use, unaware of data showing that reduced dosage helped manage adverse events.
Cadent's Solution: 360-degree, new indication launch built advocacy to satisfy combination use concerns. We created and deployed a Med Education program including a content deck, and video development, bureau of speakers, live and virtual programs, case-based round tables, product theaters, satellite symposia, on-demand video—followed by KOL identification, profiling, and mapping via a proprietary profiling database. Combination promotional speaker decks addressed sequencing and combinations with several other drugs.